Updated results from a Phase II trial of Threshold's (THLD) TH-302 treatment suggest that the...

|About: Threshold Pharmaceuticals... (THLD)|By:, SA News Editor

Updated results from a Phase II trial of Threshold's (THLD) TH-302 treatment suggest that the drug can be used in patients with soft-tissue sarcoma, first in combination with chemotherapy doxorubicin, and then on its own as a maintenance treatment. The results support Phase III trials of the regimen. Threshold shares +10.3%. (PR)